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OBJECTIVE — Visceral obesity is shown to be a predictor of morbidity and mortality. We
evaluated the association of measurements of generalized adiposity and visceral fat area (VFA),
with abnormalities of metabolic syndrome (MS).
RESEARCH DESIGN AND METHODS — Seventy-six women (47.9 9.2 years) with
BMI of 38.7  5.4 kg/m2 underwent anthropometric measurements, laboratory procedures,
bioeletrical impedance, and abdominal computed tomography (CT) scan. Diagnosis of MS was
based on the presence of abdominal obesity and at least two of the following components:
hypertension, dyslipidemia, and glucose intolerance and/or hyperinsulinemia.
RESULTS — BMI was correlated with both components of adipose tissue—subcutaneous
(r 0.66, P 0.01) and VFA (r 0.33, P 0.02)—and leptin levels (r 0.38, P 0.01). In
contrast, VFA was correlated with 2-h glucose and insulin levels (r 0.32 and 0.35, P 0.05,
respectively), triglyceride, HDL cholesterol, and uric acid (r 0.33, –0.34 and 0.24, P 0.05,
respectively). Subjects with high VFA, matched for BMI, showed greater plasma glucose area
under the curve (621 127 vs. 558 129 mg  h1  dl1, P 0.05), 2-h insulin (804 599
vs. 579 347 pmol/l, P 0.05), and uric acid levels (0.33 0.07 vs. 0.26 0.06 mmol/l, P
0.05) than subjects with low VFA. In logistic regression analysis, waist circumference, VFA, and
2-h insulin were identified as independent predictors of MS. Receiver operating characteristic
curve analysis pointed out the values of 104 cm for waist circumference (58.1% specificity,
84.1% sensitivity), 158.5 cm2 for VFA (78.1% specificity, 52.3% sensitivity), and 559.8 pmol/l
for 2-h insulin (71.9% specificity, 69.8% sensitivity); the presence of at least two of the three
variables resulted in a degree of concordance of 76%.
CONCLUSIONS — While BMI was unable to differentiate between obese people and those
at higher risk for MS, abdominal fat was shown to be associated with its metabolic abnormalities.
The usefulness of abdominal fat in the identification of high-risk subjects may be improved when
combined with 2-h insulin determination.
Diabetes Care 26:1725–1730, 2003
Obesity is considered a major publichealth problem due to its increasingprevalence and high morbidity and
mortality, mainly attributed to abnormal-
ities included in the spectrum of the met-
abolic syndrome (MS) (1–3). Particularly,
upper-body obesity has been shown to be
an important predictor of cardiovascular
disease (4). The search for markers able to
identify subjects at high risk to develop
MS is motivated by the potential benefits
of early interventions.
The simplicity of BMI assessment has
made this widely used to classify subjects’
risk of morbidity and mortality (1,5).
However, BMI is not accurate to quantify
body fat excess or the distribution of fat-
ness. Recent studies have reported popu-
lations with low prevalence of obesity but
high incidence of typical disturbances of
MS (6,7), thereby raising the question of
whether BMI plays a role in the identifi-
cation of patients at high cardiovascular
risk (8,9).
Since 1956, the impact of body fat
distribution on the occurrence of meta-
bolic abnormalities in obese people has
received increased attention (10). Nowa-
days, abdominal fat accumulation is seen
as key event for the pathogenesis of the
MS (11,12). However, the impact of vis-
ceral fat on mortality of patients with MS
is not completely known due to limita-
tions, such as availability, radiation, high
costs, and low specificity of the anthro-
pometry (waist circumference or waist-
to-hip ratio [WHR]), in the assessment of
visceral fat by computed tomography
(CT)—the gold standard. Also, data con-
cerning the cutoff values for CT-deter-
mined intra-abdominal fat associated
with high cardiovascular risk are not
widely available (13,14).
This study aimed to evaluate the as-
sociation of measurements of generalized
(expressed by the BMI) and visceral adi-
posity (CT-determined visceral fat area)
with typical abnormalities of MS.
RESEARCH DESIGN AND
METHODS — Patients aged 20 – 65
years with BMI30 kg/m2 were recruited
from the Clinic of Obesity of the Federal
University of Sa˜o Paulo. Written informed
consent was obtained from all partici-
pants, and the study was approved by the
Institutional Ethics Committee. Exclu-
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sion criteria were patients with self-
reported diabetes, severe dyslipidemia
(total cholesterol9.0 mmol/l and/or tri-
glyceride 4.5 mmol/l), weight loss 3
kg in the last 3 months, cause-specific
obesity, use of medication that could po-
tentially affect lipid or glucose metabo-
lism, and systolic and diastolic blood
pressure160/110 mmHg. In this cross-
sectional study, patients were submitted
to anthropometric measurements and
clinical examination, and data were taken
by the same investigator. BMI was calcu-
lated as weight (kilograms) divided by
height (meters) squared. WHR was calcu-
lated as the ratio of waist (measured at the
midpoint between the lateral iliac crest
and lowest rib) to the hip (at the level of
the trochanter major) circumferences.
Blood pressure was taken after a 5-min
resting in the sitting position by standard
sphygmomanometry. Hypertension was
defined by systolic or diastolic blood
pressure130/85 mmHg or by the use of
antihypertensive medications (15). Body
fat mass was estimated with a single-
frequency (50 kHz) battery-operated bio-
impedance analyzer (model BIA 101Q;
RJL System, Clinton, MI). A tetrapolar
placement of electrodes was used accord-
ing to the manufacturer’s instructions.
Fasting subjects rested supine on a couch
for 15 min in a thermoneutral (24–26°C)
room, without touching any metallic ob-
ject. Weight, height, age, and sex were
entered into the bioimpedance analyzer
(BIA) machine for analysis with the mea-
sured bioelectrical impedance to calculate
body composition from the manufactur-
er’s equations. Subcutaneous (SFA) and
visceral fat areas (density –50 –250 HU)
were obtained by CT scan in a single to-
mographic slice at the L4-L5 level, ex-
pressed as cent imeters squared.
Laboratory evaluation included a 75-g
oral glucose tolerance test for plasma glu-
cose and insulin determinations, lipid
profile (total cholesterol and fractions, tri-
glyceride, and apolipoprotein B), uric
acid, and leptin concentrations. Given
that there is no internationally agreed
upon definition for MS, in the present
study MS was based on the presence of
abdominal obesity and at least two of the
following components: hypertension,
dyslipidemia, and glucose intolerance
and/or hyperinsulinemia (fasting insulin
145 pmol/l). Because all patients were
obese and had waist circumference 88
cm for women, such measurement was
not used as a diagnostic parameter. Both
fasting and 2-h plasma glucose values
were used to diagnose the glucose toler-
ance status. Serum lipids and blood pres-
sure cutoffs follow National Cholesterol
Education Program (NCEP) criteria (15).
Insulin resistance index was estimated by
homeostasis model assessment (HOMA)
and glucose area under the curve.
Plasma glucose was determined by
the glucose-oxidase method. Cholesterol
contents of lipoprotein fractions and se-
rum triglyceride were measured enzymat-
ically. Insulin was determined by mono-
clonal antibody-based immunofluorimet-
ric assay (Delfia) and leptin by radioim-
munoassay (Linco).
Statistical analysis included unpaired
Student’s t test to compare means of clin-
ical and laboratory data between groups
of subjects stratified by BMI and visceral
fat area (VFA). Data were given as the
mean and standard deviation. Pearson
and Spearman coefficients were used to
test correlation between variables. Inde-
pendent associations of variables with MS
were analyzed by logistic regression. Re-
ceiver operating characteristic (ROC)
curve analysis was used to establish cut
points for a number of variables associ-
ated with the occurrence of MS.  statis-
tics were used to assess the concordance
with the diagnosis of MS. Level of signif-
icance was set at P  0.05. Data analysis
was performed using software SPSS 10.0.
Table 1—Correlation coefficients of BMI, SFA, and VFA with anthropometric, metabolic, and hormonal parameters and percent body fat
BMI SFA VFA
r P r P r P
Waist circumference 0.78 0.01 0.55 0.01 0.56 0.01
Hip circumference 0.76 0.01 0.60 0.01 0.10 0.10
WHR 0.34 0.01 0.18 0.10 0.58 0.01
Fat mass 0.71 0.01 0.48 0.01 0.27 0.02
Subcutaneous fat by CT 0.66 0.01 — — 0.16 0.10
Visceral fat by CT 0.33 0.01 0.16 0.10 — —
Fasting plasma glucose 0.29 0.01 0.01 0.10 0.22 0.05
2-h plasma glucose 0.13 0.10 0.08 0.10 0.32 0.01
Glucose area under curve 0.15 0.10 0.08 0.10 0.35 0.01
Fasting insulin 0.16 0.10 0.15 0.10 0.30 0.01
2-h insulin 0.12 0.10 0.12 0.10 0.35 0.01
HOMA index 0.18 0.10 0.12 0.10 0.30 0.01
Total cholesterol 0.10 0.10 0.09 0.10 0.09 0.10
HDL cholesterol 0.24 0.03 0.07 0.10 0.34 0.01
LDL cholesterol 0.04 0.10 0.05 0.10 0.09 0.10
Apolipoprotein B 0.02 0.10 0.10 0.10 0.21 0.10
Triglyceride 0.05 0.10 0.07 0.10 0.33 0.01
Uric acid 0.25 0.03 0.20 0.08 0.24 0.04
Leptin 0.38 0.01 0.27 0.02 0.03 0.10
MS* 0.33 0.01 0.14 0.10 0.36 0.01
*Presence of abdominal obesity and at least two of the following components: hypertension, dyslipidemia, and glucose intolerance and/or hyperinsulinemia.
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RESULTS — Seventy-six patients aged
47.9 9.2 years, with a predominance of
Caucasians (66%), having a BMI of
38.7 5.4 kg/m2 were included. Eighty-
seven percent (n  66) were hyperten-
sive, glucose intolerance was diagnosed in
41%, 82% had dyslipidemia, and 35%
had hyperinsulinemia. Fifty-eight percent
(n  44) fulfilled criteria for MS.
Correlation coefficients between BMI,
SFA, or VFA and a number of variables are
shown in Table 1. VFA was found to be
correlated with metabolic parameters
characteristic of MS, such as triglyceride,
HDL cholesterol, and uric acid levels, as
well as 2-h post–glucose load glycemia,
insulinemia, and insulin resistance index.
BMI showed significant correlation with
fasting plasma glucose, HDL cholesterol,
uric acid levels, leptin, percent of body fat
mass, waist and hip circumferences, and
VFA and SFA determined by CT scan.
Multiple linear regression indicated that
both visceral and subcutaneous fat, but
mainly the latter, were independent pre-
dictors of BMI (r2  0.48, P  0.001).
Patients were then stratified into
groups defined by “matched BMIs” or
“matched VFAs” (Table 2). For stratifica-
tion by matched BMIs, from each pair of
subjects, the individuals with the higher
VFAs comprised the subgroup “more cen-
tralized adiposity”; for stratification by
matched VFAs, the individuals with
higher BMIs comprised the subgroup of
“more generalized adiposity.” Therefore,
groups divided according to BMI showed
similar VFAs, and those divided accord-
ing to VFA showed similar BMIs. Com-
paring groups of subjects with matched
VFAs, those with higher BMI (more gen-
eralized adiposity) also had significantly
higher waist circumference, percent of
body fat mass, and SFA. When groups
with matched BMIs were compared, those
with higher VFA (more centralized adi-
posity) showed higher waist circumfer-
ence, 2-h plasma glucose and insulin
levels, glucose area under the curve, and
triglyceride and uric acid levels. The con-
trast in glycemic curves and insulin values
obtained for subjects with matched VFAs
and matched BMIs is depicted in Fig. 1.
Forty-four patients with MS showed
higher BMI and adipose depots in the ab-
dominal region (reflected by the waist cir-
cumference and WHR), fasting and 2-h
insulin, HOMA index, and VFA, but not
SFA, determined by CT (Table 3).
When patients were categorized ac-
cording to normal glucose tolerance
(NGT, n  45), impaired glucose toler-
ance (IGT, n  25), or diabetes (n  6),
the VFAs (129.0  54.4, 153.0  59.3,
and 192.5  48.7, for NGT, IGT, and
diabetes, respectively, P  0.05) but not
BMIs (37.8 5.0, 40.6 6.0, and 38.1
4.0) were higher in those with distur-
bances of glucose metabolism.
In the logistic regression analysis, age,
BMI, VFA, SFA, waist circumference, fast-
ing and 2-h insulin, and leptin were en-
tered into the model as variables of
interest in the association with MS. Waist
circumference, VFA, and 2-h insulin were
shown to be independently associated
with MS. Using the ROC curve, the values
of 104 cm for waist circumference (58.1%
specificity, 84.1% sensitivity, positive
predictive value of 74.0%, and negative
predictive value of 72.0%), 158.5 cm2 for
VFA (78.1% specificity, 52.3% sensitiv-
ity, positive predictive value of 76.7%,
and negative predictive value of 54.3%),
Table 2—Anthropometric, hemodynamic, and metabolic parameters of groups of patients with matched BMI or VFA
Matched BMI Matched VFA
Less centralized
(n  38)
More centralized
(n  38)
Less generalized
(n  38)
More generalized
(n  38)
Age (years) 45.1  10.7 50.7  6.3* 48.0  9.6 47.8  8.9
BMI (kg/m2) 38.4  5.9 39.1  4.9 36.8  4.0 40.7  5.9*
Waist circumference (cm) 105.5  13.5 114.9  11.3* 107.0  12.0 113.6  13.8*
WHR 0.90  0.09 0.99  0.07* 0.95  0.09 0.95  0.10
Fat mass (%) 42.5  5.4 44.0  4.4 41.7  4.8 44.8  4.7*
Visceral fat by CT (cm2) 101.0  34.2 182.9  47.0* 143.3  60.5 140.6  56.1
Subcutaneous fat by CT (cm2) 374.0  124.7 383.3  128.7 332.3  110.8 424.9  124.3*
Systolic blood pressure (mmHg) 147.0  21.2 152.5  19.5 151.4  23.4 148.0  17.0
Diastolic blood pressure (mmHg) 93.6  10.6 96.0  10.0 93.9  10.8 95.7  9.9
Heart rate (bpm) 79.0  6.4 77.7  8.0 78.3  7.7 78.4  6.8
Fasting plasma glucose (mmol/l) 5.2  0.7 5.4  0.6 5.2  0.5 5.4  0.7
2-h plasma glucose (mmol/l) 6.8  2.2 7.8  2.4* 7.2  2.4 7.3  2.3
Glucose area under curve (mg  h1  dl1) 557.8  129.3 621.1  126.6* 583.1  118.3 595.8  144.0
Fasting insulin (pmol/l) 113.7  64.3 132.1  65.9 120.3  57.4 125.6  73.2
2-h insulin (pmol/l) 578.7  346.7 804.2  599.1* 757.8  609.6 620.3  341.8
HOMA index 3.7  2.4 4.4  2.2 3.9  2.0 4.2  2.6
Total cholesterol (mmol/l) 5.3  1.0 5.3  1.0 5.3  1.0 5.3  1.0
HDL cholesterol (mmol/l) 1.1  0.3 1.0  0.2* 1.0  0.3 1.1  0.3
LDL cholesterol (mmol/l) 3.4  0.9 3.5  0.9 3.5  0.9 3.4  0.9
Apolipoprotein B (g/l) 1.22  0.27 1.36  0.29† 1.30  0.28 1.31  0.30
Triglyceride (mmol/l) 1.4  0.6 2.0  0.8* 1.7  0.8 1.7  0.7
Uric acid (mmol/l) 0.29  0.06 0.33  0.07* 0.30  0.50 0.31  0.11
Leptin (ng/ml) 26.3  19.3 26.3  13.3 20.9  13.0 31.3  14.0*
Data are means  SD. *P  0.05 vs. group less centralized or generalized; †P  0.07 vs. group less centralized or generalized.
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and 559.8 pmol/l for 2-h insulin (71.9%
specificity, 69.8% sensitivity, positive
predictive value of 76.9%, and negative
predictive value of 63.9%) were found to
be the best indicators of MS. Insulin levels
and waist circumference were concordant
with MS diagnosis in 71% of patients (
0.41 and 0.43, respectively, P 0.01, for
both), whereas the concordance of VFA
was 63% ( 0.29, P  0.01). Taken into
consideration the three variables, the
presence of at least two resulted in a de-
gree of concordance of 76% ( 0.50, P
0.001).
CONCLUSIONS — Obesity is a well-
known risk factor for diabetes, hyperten-
sion, and dyslipidemia, all of which
elevate cardiovascular mortality (1,2,5).
The benefits of intervening in obesity
have been shown (1), particularly in re-
gard to the prevention of diabetes (16).
Among obese subjects, the identification
of those at higher risk to develop such
diseases would improve effectiveness of
prevention strategies. Despite the associ-
ation of elevated body fatness, as reflected
by high BMI, with morbidity and cardio-
vascular mortality (1,5), reports of popu-
lations at high risk for cardiovascular
disease but with low prevalence rates of
obesity are also found in literature (6,7).
In addition, the findings of obese people
without metabolic disturbances raise
questions concerning the role of BMI as
an isolated marker of risk (8,9).
Insulin resistance has been shown as
the link between intra-abdominal adipos-
ity and metabolic and hemodynamic ab-
normalities (3,8). Arner (17) proposed
the “portal theory,” in which free fatty ac-
ids released from the visceral adipose tis-
sue could be a trigger factor to reduce
insulin sensitivity, elevate insulin levels,
and provoke a number of typical distur-
bances of the MS. Several lines of evidence
have supported a more deleterious role of
visceral fat relative to subcutaneous fat
(3,8,18). However, a causal relationship
of visceral adiposity with the insulin resis-
tance syndrome is not a consensus
(11,19). A recent study indicated that
subcutaneous adipose tissue is the main
source of free fatty acids (19). Goodpas-
teur et al. (20) found correlation of the
subcutaneous abdominal fat with charac-
teristic features of the insulin resistance.
Thus, the assessment of adipose tissue
distribution and its relationship with
morbidity is of great interest in order to
identify subjects at high cardiovascular
risk.
In the present study, VFA determined
by CT, but not the BMI or SFA, was asso-
ciated with metabolic abnormalities such
as reduced HDL cholesterol; elevated tri-
glyceride, apolipoprotein B, and uric acid
levels; and disturbed insulin sensitivity
expressed by the HOMA index. Our find-
ings are in agreement with others who
emphasized the importance of visceral
adipose tissue for the genesis of insulin
resistance syndrome (3,7,18,21). Strong
correlation was detected between BMI
and leptin, the levels of which are known
to be proportional to the subcutaneous fat
(22). This may suggest that BMI is inap-
Figure 1—Glycemic curves and insulin values obtained for subjects with matched VFA (A) and
for those with matched BMI (B). P  0.05 vs. lower VFA group.
Table 3—Anthropometric and hormonal characteristics according to the presence of MS
Without MS
(n  32)
With MS
(n  44)
Age (years) 47.2  10.6 48.4  8.1
BMI (kg/m2) 36.9  5.0 40.1  5.4*
Waist circumference (cm) 103.4  13.5 115.1  10.8*
WHR 0.91  0.09 0.97  0.09*
Fat mass (%) 42.6  5.1 43.7  4.9
Fasting insulin (pmol/l) 88.3  32.3 147.9  71.8*
2-h insulin (pmol/l) 450.2  251.7 868.1  558.6*
HOMA index 2.8  1.0 5.0  2.5*
Leptin (ng/ml) 25.0  19.6 27.2  13.8
Subcutaneous fat by CT (cm2) 357.2  136.6 394.2  116.7
Visceral fat by CT (cm2) 119.7  56.0 158.1  54.5*
Data are means SD. *P 0.01 vs. without MS. MS was defined by presence of abdominal obesity and at
least two of the following components: hypertension, dyslipidemia, and glucose intolerance and/or hyper-
insulinemia.
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propriate to reflect the intra-abdominal
fat depots.
After stratifying subjects according to
similar BMI or similar VFA, we found that
the discriminatory power of VFA was
markedly better than BMI since the
former identified patients with worse
lipid profile and higher uric acid and
postchallenge glucose levels, which are
well-recognized cardiovascular risk fac-
tors (23–25). In agreement with others
(4,9,12), our data support the indication
of measurements of fat distribution to as-
sess cardiovascular risk.
Our findings in the patients with MS,
i.e., elevated BMI accompanied by higher
VFA and insulin levels, corroborate the
hypothesis that insulin may be the factor
underlying the metabolic abnormalities
(2,3). In contrast, the involvement of lep-
tin in this syndrome, as suggested by
some investigators (26), was not sup-
ported in our study.
Waist circumference, VFA deter-
mined by CT, and postchallenge insulin
levels were found to be independent pre-
dictors of MS. Hyperinsulinemia was pre-
viously reported as an independent
cardiovascular risk factor (27). More re-
cently, the importance of altered post-
prandial glycemia was demonstrated in
epidemiological study (23 ). Our findings
supported the investigation of the impact
of 2-h insulinemia for the cardiovascular
risk. Such factor seemed to be relevant
even more than BMI and leptin levels in
our regression model. We propose that
much of the importance of BMI for mor-
bidity and mortality should be attributed
to the visceral component of the body fat-
ness. Such a hypothesis is reinforced by
the fact that the proportion of the visceral
component increases as BMI elevates
(28,29). The inclusion of only obese sub-
jects limited to test this hypothesis in our
sample. Additional evidence on the rele-
vance of fatness distribution was reported
by Egger (9), who showed that nonobese
subjects with abdominal adiposity are at
higher cardiovascular risk than those
obese subjects with gluteal-femoral adi-
posity.
Cut points for anthropometric pa-
rameters associated with increased risk of
morbidities have been suggested (30,31).
Despite the significant correlations be-
tween waist circumference and WHR
with VFA observed in this study, a num-
ber of limitations of these measurements
can be identified. The technical proce-
dure includes quantification of also the
subcutaneous adipose tissue located in
the abdominal wall. Additionally, such
measurements are related to high inter-
ethnic variation and considerable inter-
and intra-examiner variation, which lim-
its the applicability of the measurements
in clinical evaluation of visceral fat depots
(32). On the other hand, scant studies are
available that suggest cut points for CT-
determined visceral fat, which is associ-
ated with cardiovascular risk factors
(13,14). This study proposes that a com-
bination of an anatomical measurement,
such as waist circumference (high sensi-
tivity) and/or VFA (high specificity), with
a metabolic parameter, such as the 2-h
insulin determination, which improves
the diagnostic concordance, could be use-
ful to identify subjects at high risk for de-
veloping MS. High cutoff points found in
this study may be explained by the inclu-
sion of obese subjects only.
In conclusion, isolated BMI measure-
ment is not a precise marker of risk in
obese subjects, in contrast with abdomi-
nal fat, which shows significant correla-
tions with typical abnormalities of the
MS. When associated with the 2-h insulin
level, abdominal fat may be useful to more
precisely identify patients at high cardio-
vascular risk. Longitudinal studies are
needed to define VFA and waist circum-
ference cutoffs predictive of mortality.
Considering the high costs of CT scan,
alternative methods with high specificity
to assess visceral fat are desirable.
Acknowledgments— We thank Fundac¸a˜o
de Amparo a` Pesquisa do Estado de Sa˜o Paulo
(FAPESP) for financial support of the publica-
tion fees for this article.
References
1. World Health Organization: Obesity: Pre-
venting and Managing the Global Epidemic.
Report of a WHO Consulation on Obesity.
Geneva, World Health Organization,
1997 (Tech. Rep. Ser., no. 894)
2. Reaven GM. Syndrome X: 6 years later.
J Intern Med 736 (Suppl.):13–22, 1994
3. Timar O, Sestier F, Levy E: Metabolic syn-
drome X: a review. Can J Cardiol 16:779–
789, 2000
4. Lamarche B, Lemieux S, Dagenais GR,
Depres JP: Visceral obesity and the risk of
ischaemic heart disease: insights from the
Quebec Cardiovascular Study. Growth
Horm IGF Res 8:1–8, 1998
5. Calle EE, Thun MJ, Petrelli JM, Rodriguez
C, Heath CW Jr: Body mass index and
mortality in a prospective cohort of US
adults. N Engl J Med 341:1097–1105,
1999
6. Anderson PJ, Chan JCN, Chan YL, Tom-
linson B, Young RP, Lee KKC, Metrewell
C, Cockram CS, Critchley JAJH: Visceral
fat and cardiovascular risk factors in Chi-
nese NIDDM patients. Diabetes Care 20:
1854–1858, 1997
7. Chen CH, Lin KC, Tsai ST, Chou P: Dif-
ferent association of hypertension and
insulin-related metabolic syndrome be-
tween men and women in 8437 nondia-
betic Chinese. Am J Hypertens 13:846–
853, 2000
8. Matsunaga Y: Pathophysiology and mo-
lecular mechanisms of visceral fat syn-
drome: the Japanese experience. Diabete
Metab Rev 13:3–13, 1997
9. Egger G: The case for using waist to hip
ratio measurements in routine medical
checks. Med J Aust 156:280–285, 1992
10. Vague J: The degree of masculine differ-
entiation of obesity: a factor determining
predisposition to diabetes, atherosclero-
sis, gout, and uric acid calculous disease.
Am J Clin Nutr 4:20–34, 1956
11. Wajchenberg BL: Subcutaneous and vis-
ceral adipose tissue: their relation to the
metabolic syndrome. Endoc Rev 21:697–
738, 2000
12. Despres JP, Lemieux I, Prud’Homme D:
Treatment of obesity: need to focus on
high risk abdominal obese patients. BMJ
322:716–720, 2001
13. Williams MJ, Hunter GR, Kekes-Szabo T,
Trueth MS, Snyder S, Berland L, Blaudeau
T: Intra-abdominal adipose tissue cut-
points related to elevated cardiovascular
risk in women. Int J Obes 20:613–617,
1996
14. Despre´s JP, Lamarche B: Effects of diet
and physical activity on adiposity and
body fat distribution: implications for the
prevention of cardiovascular disease. Nutr
Res Rev 6:137–159, 1993
15. Ford ES, Giles WH, Dietz WH: Prevalence
of the metabolic syndrome among US
adults findings from the third national
health and nutrition examination survey.
JAMA 287:356–359, 2002
16. Diabetes Prevention Program Research
Group: Reduction in the incidence of type
2 diabetes with lifestyle intervention or
Metformin. N Engl J Med 346:1393–1403,
2001
17. Arner P: Catecholamine-induced lipolysis
in obesity. Int J Obes 23 (Suppl.1):S10–
S13, 1999
18. Frayn KN: Visceral fat and insulin resis-
tance: causative or correlative? Br J Nutr
83 (Suppl. 1):S71–S77, 2000
19. Guo Z, Hensrud DD, Johnson CM, Jensen
MD: Regional postprandial fatty acid me-
tabolism in different obesity phenotypes.
Ribeiro-Filho and Associates
DIABETES CARE, VOLUME 26, NUMBER 6, JUNE 2003 1729
Diabetes 48:1586–1592, 1999
20. Goodpaster BH, Thaete FL, Simoneau JA,
Kelley DE: Subcutaneous abdominal fat
and thigh muscle composition predict in-
sulin sensitivity independently of visceral
fat. Diabetes 46:1579–1585, 1997
21. Pouliot MC, Despre´s JP, Nadeau A, Moor-
jani S, Prud’Homme D, Lupien PJ, Trem-
blay A, Bouchard C: Visceral obesity in
men: associations with glucose tolerance,
plasma insulin, and lipoprotein levels. Di-
abetes 41:826–834, 1992
22. Harmelen VV, Reynisdottir S, Eriksson P,
Tho¨rne A, Hoffstedt J, Lo¨nnqvist F, Arner
P: Leptin secretion from subcutaneous
and visceral adipose tissue in women. Di-
abetes 47:913–917, 1998
23. European Diabetes Epidemiology Group:
Glucose tolerance and mortality: compar-
ison of WHO and American Diabetes As-
sociation diagnostic criteria. The DECODE
study group. Lancet 354:617–621, 1999
24. Fang J, Alderman MH: Serum uric acid
and cardiovascular mortality. The
NHANES I epidemiologic follow-up
study, 1971–1992. JAMA 283:2404–2410,
2000
25. Lennep JERV, Westerveld T, Lennep
HWORV, Zwinderman AH, Erkelens
DW, Wall EEVD: Apolipoprotein concen-
trations during treatment and recurrent
coronary artery disease events. Arterioscler
Thromb Vasc Biol 20:2408–2413, 2000
26. Courten M, Zimmet P, Hodge A, Collins
V, Nicolson M, Staten M, Dowse G, Al-
berti KGMM: Hyperleptinaemia: the
missing link in the metabolic syndrome?
Diabet Med 14:200–208, 1997
27. Pyorala M, Miettinen H, Laakso M,
Pyorala K: Plasma insulin and all-cause,
cardiovascular, and noncardiovascular
mortality: the 22-year follow-up results of
the Helsinki Policemen Study. Diabetes
Care 23:1097–1102, 2000
28. Seidell JC, Oosterlee A, Deurenberg P,
Hautvast JGAJ, Ruijs JHJ: Abdominal fat
depots measured with computed tomog-
raphy: effects of degree of obesity, sex,
and age. Eur J Clin Nutr 42:805–815, 1988
29. Ro¨nnemaa T, Koskenvuo M, Marniemi J,
Koivunen T, Sajantila A, Rissanen A, Kait-
saari M, Bouchard C, Kaprio J: Glucose
metabolism in identical twins discordant
for obesity: the critical role of visceral fat.
J Clin Endocrinol Metab 82:383–387, 1997
30. Han TS, Leer EM, Seidell JC, Lean MEJ:
Waist circumference action levels in the
identification of cardiovascular risk fac-
tors: prevalence study in a random sam-
ple. BMJ 311:1401–1405, 1995
31. Bray GA, Gray DS: Treatment of obesity:
an overview. Diabete Metab Rev 4:653–
679, 1988
32. Okosun IS, Tedders SH, Choi S, Dever
GEA: Abdominal adiposity values associ-
ated with established body mass indexes
in white, black and Hispanic Americans: a
study from the NHANES III. Int J Obes
24:1279–1285, 2000.
Abdominal fat and metabolic syndrome
1730 DIABETES CARE, VOLUME 26, NUMBER 6, JUNE 2003
